ライフサイエンスコーパス: fulminant liver failure

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 or patients with decompensated cirrhosis and fulminant liver failure.

2 rosis factor (TNF)-mediated murine models of fulminant liver failure.

3 tation is wide, varying from mild disease to fulminant liver failure.

4 neurological disability, then developed sub-fulminant liver failure.

5 ed in a variety of diseases, including acute fulminant liver failure.

6 history of a febrile illness presented with fulminant liver failure.

7 eutic strategy for hepatic disorders such as fulminant liver failure.

8 The patient died due to fulminant liver failure 14 months later; the histopathol

9 massive hepatocyte apoptosis and subsequent fulminant liver failure and death in D-GalN-sensitized m

10 ients with Wilson's disease who present with fulminant liver failure and for patients unresponsive to

11 r transplantation (LT) between patients with fulminant liver failure and those with cirrhosis and sev

12 pression can lead to severe acute hepatitis, fulminant liver failure, and death.

13 dinedione sometimes, although rarely, led to fulminant liver failure, and ultimately the drug was rem

14 We previously reported that acute fulminant liver failure associated with B19 virus infect

15 is currently the only effective therapy for fulminant liver failure, but its use is limited by the s

16 nitive treatment for end-stage cirrhosis and fulminant liver failure, but the lack of available donor

17 h is frequently up-regulated in HCCs, delays fulminant liver failure in mice by inhibiting apoptosis,

18 followed by 6 hours of reperfusion induced a fulminant liver failure in WT and Stat6 KO mice, as asse

19 patient who is admitted urgently with acute (fulminant) liver failure in whom consent may not be poss

20 SCs) protect from death in a lethal model of fulminant liver failure induced by intraperitoneal injec

21 These data suggest that fulminant liver failure may potentially benefit from tre

22 rnative medicine agents are a major cause of fulminant liver failure necessitating liver transplantat

23 ed liver injury has been described involving fulminant liver failure or death.

24 or definite AIH) among the 70 patients with fulminant liver failure was 24% for simplified criteria

25 cluding a subset of patients presenting with fulminant liver failure who required liver transplant.

26 DNA, but not control non-CpG DNA, induces a fulminant liver failure with subsequent shock-mediated d

27 nt treatment also prevents TNFalpha-mediated fulminant liver failure without affecting liver regenera

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。